Supplementary Material 0012-6667/07/0015-0001/$49.95/0 Review Article © 2007 Adis Data Information BV

Supplementary Material 0012-6667/07/0015-0001/$49.95/0 Review Article © 2007 Adis Data Information BV

Drugs 2007; 67 (16): Supplementary Material 0012-6667/07/0015-0001/$49.95/0 Review Article © 2007 Adis Data Information BV. All rights reserved. Multidrug-Resistant Streptococcus pneumoniae Infections Current and Future Therapeutic Options Françoise Van Bambeke,1 René R. Reinert,2 Peter C. Appelbaum,3 Paul M. Tulkens,1 and Willy E. 4 Peetermans 1 Unité de Pharmacologie Cellulaire et Moléculaire, Université Catholique de Louvain, Brussels, Belgium 2 Institute for Medical Microbiology, National Reference Center for Streptococci, University Hospital (RWTH), Aachen, Germany 3 Department of Pathology, Hershey Medical Center, Hershey, Pennsylvania, USA 4 Department of Internal Medicine-Infectious Diseases, Katholieke Universiteit Leuven, University Hospital Gasthuisberg, Leuven, Belgium Supplementary Material This supplementary material contains the figures referred to in the full version of this article, which can be found at http://drugs.adisonline.com. Figure 1. Chemical structures of reference cephalosporins and of derivatives in development that are characterised by a high in vitro activity towards S. pneumoniae. H H R1 N S O N R O 2 HO O drug -R1 -R2 O ONH2 cefuroxime H C N 3 O O H2N S SN NH ceftriaxone N N O H3C N O O S O cefotaxime NH2 H3C N N O O NH2 S CH3 N cefditoren N S N OCH3 NH2 S NN N ceftobiprole NH O N OH NH2 S NN N cefmatilen N SSN H N OH H N PO3H2 S S NN S ceftaroline N N CH3 N OEt NH2 S N N Cl RWJ-54428 S NH N 3 S OH Figure 2. Chemical structures of a reference carbapenem and of derivatives in development that are characterised by a high in vitro activity towards S. pneumoniae. OH H H SR N OH O O drug -R S imipenem N NH H faropenem O O NH H S N N N NH2 CS-023 H N O CH3 Figure 3. Chemical structures of reference glycopeptides and of derivatives in development that are characterised by a high in vitro activity towards S. pneumoniae. HOHO O OH O O CH R HN 3 1 O Cl R2 H3C O O R3 R4 O OH Cl O O O H H N N N N NH H H HN O O NHCH3 CONH2 O HOOC OH HO OH R5 drug -R1 -R2 -R3 -R4 -R5 vancomycin -H -OH -H -H -H H2N HO Cl oritavancin -H -OH H3C O -H CH3 telavancin H -OH -H -H NH N PO3H2 CO R1 HN HO HO O O R2 O O R3 Cl O O O H H O N N NHCH3 N N N H H H HN O Cl O R4 HO O OH OH HO O OH O OH OH OH -R1 -R2 -R3 -R4 O OH HO teicoplanin -CH3OH HO O -COOH NHAc dalbavancin -COOH -OH N NH CO Figure 4. Chemical structures of a reference ketolide and of derivatives in development that are characterised by a high in vitro activity towards S. pneumoniae. N N O N O H C H3C 3 CH3 CH3 N O OCH3 O O H C N CH 3 3 H3C NH CH3 (H C) N 3 2 (H3C)2N H3C O HO O H3C H3CH2C O O HO O CH3 H3CH2C O O O CH3 O O O O CH3 CH3 telithromycin cethromycin N N N N N O O N N O O H3C CH3 H C N 3 CH3 O O HO O O H C CH 3 3 H3C NH CH3 (H3C)2N (H C) N H C 3 2 3 O H3C H CH C O OHO HO 3 2 O H3CH2C O O CH3 O CH3 O O O O F CH3 CH3 EDP-420 FMA-1485 Figure 5. Chemical structures of a reference lincosamide and of a derivative in development that is characterised by a high in vitro activity towards S. pneumoniae. O R 1 R2 NH O HO SCH3 HO OH drug -R1 -R2 Cl N clindamycin VIC105555 N H Figure 6. Chemical structures of a reference oxazolidinone and of a derivative in development that is characterised by a high in vitro activity towards S. pneumoniae. O HN R N O F O drug -R linezolid O N O2N ranbezolid O N N Figure 7. Chemical structures of reference tetracyclines and of derivatives in development that are characterised by a high in vitro activity towards S. pneumoniae. N R2 R1 R3 HH OH NH2 R4 OH OH O OH O O drug -R4 -R3 -R2 -R1 tetracycline -H -OH -H -H doxycycline -H -CH3 -H -OH O H N -H -N(CH ) -CH tigecycline N 3 2 3 H H PTK-0796 N -H -N(CH3)2 -CH3 Figure 8. Chemical structures of reference quinolones and of derivatives in development that are characterised by a high in vitro activity towards S. pneumoniae. R5 O R6 COOH R7 X N R8 R1 drug X -R8 -R1 -R5 -R6 -R7 C N levofloxacin -H -F NN O CH3 H H N N moxifloxacin C -O-CH3 -H -F H O N -H -F N gemifloxacin N NH2 HN garenoxacin C -O-CHF2 -H -H N sitafloxacin C -Cl -H -F F H2N C N WCK-771 -H -F HO NN O CH3 CH3 H3C WCK-1152 C -O-CH3 -H -F NH2 N CH3 H3C WCK-1153 C -O-CH3 -H -F H2N N DX-619 C -O-CH3 -H -F N NH2 F N DK-507k C -O-CH3 -H -F F H2N N DC-159a C -O-CH3 -H -F F CH3 NH2 N HN DW-224a N -H -F N O NH2 PGE 9262932 C -O-CH3 -H -F N H N olamufloxacin C -CH3 -NH2 -F H2N Figure 9. Chemical structures of a reference diaminopyridine and of derivatives in development that are characterised by a high in vitro activity towards S. pneumoniae. H NNNH 2 2 N R drug -R trimetoprim O O O iclaprim O O O O O N AR-709 O O NH Cl .

View Full Text

Details

  • File Type
    pdf
  • Upload Time
    -
  • Content Languages
    English
  • Upload User
    Anonymous/Not logged-in
  • File Pages
    12 Page
  • File Size
    -

Download

Channel Download Status
Express Download Enable

Copyright

We respect the copyrights and intellectual property rights of all users. All uploaded documents are either original works of the uploader or authorized works of the rightful owners.

  • Not to be reproduced or distributed without explicit permission.
  • Not used for commercial purposes outside of approved use cases.
  • Not used to infringe on the rights of the original creators.
  • If you believe any content infringes your copyright, please contact us immediately.

Support

For help with questions, suggestions, or problems, please contact us